{"id":352910,"date":"2025-08-26T08:37:09","date_gmt":"2025-08-26T08:37:09","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-denali-therapeutics\/"},"modified":"2025-08-26T08:37:09","modified_gmt":"2025-08-26T08:37:09","slug":"how-to-buy-denali-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/","title":{"rendered":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-352910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Denali Therapeutics (DNLI) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve bu umut vadeden biyoteknoloji \u015firketi i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcrecini \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Denali Therapeutics (DNLI) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve bu umut vadeden biyoteknoloji \u015firketi i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcrecini \u00f6\u011frenin."},"intro":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Denali Therapeutics, hasta bak\u0131m\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilecek \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle n\u00f6rolojik hastal\u0131k tedavisinde \u00f6nc\u00fc konumda. Bu \u015firket sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014\u015fu anda s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri olan nadir genetik hastal\u0131klar\u0131n tedavisinde potansiyel bir oyun de\u011fi\u015ftirici.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Denali Therapeutics, hasta bak\u0131m\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilecek \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle n\u00f6rolojik hastal\u0131k tedavisinde \u00f6nc\u00fc konumda. Bu \u015firket sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014\u015fu anda s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri olan nadir genetik hastal\u0131klar\u0131n tedavisinde potansiyel bir oyun de\u011fi\u015ftirici."},"body_html":"<p>\ud83d\udcc8 <strong>G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/strong><\/p> <p>26 A\u011fustos 2025 itibar\u0131yla Denali Therapeutics Inc. (DNLI) hissesi <strong>15,49 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014DNLI'nin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar hisseyi \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirmi\u015f, bazen saatler i\u00e7inde \u00e7ift haneli y\u00fczdelerle de\u011fi\u015fim g\u00f6stermi\u015ftir.<\/p> <p><strong>FDA Kararlar\u0131n\u0131n DNLI Hissesini Nas\u0131l Etkiledi\u011fi<\/strong><\/p> <p>Biyoteknoloji hisseleri d\u00fczenleyici haberlerle hayat bulur ya da biter, DNLI de istisna de\u011fil. \u015eirket yak\u0131n zamanda lider ila\u00e7 aday\u0131 tividenofusp alfa i\u00e7in <a href=\"https:\/\/www.stocktitan.net\/news\/DNLI\/denali-therapeutics-announces-fda-acceptance-and-priority-review-of-1lxq6gfuzvfz.html\">FDA taraf\u0131ndan \u00d6ncelikli \u0130nceleme kabul\u00fc<\/a> ald\u0131 ve PDUFA hedef tarihi 5 Ocak 2026 olarak belirlendi. Bu b\u00fcy\u00fck bir haber\u2014\u00d6ncelikli \u0130nceleme, FDA'n\u0131n bu tedaviyi mevcut tedavilere k\u0131yasla \u00f6nemli bir ilerleme olarak g\u00f6rd\u00fc\u011f\u00fc anlam\u0131na gelir.<\/p> <p>Tarihsel desenlere bak\u0131ld\u0131\u011f\u0131nda, olumlu FDA haberleri genellikle biyoteknoloji hisselerini tek bir g\u00fcnde %20-50 oran\u0131nda y\u00fckseltir. Tersi de do\u011frudur\u2014d\u00fczenleyici aksakl\u0131klar hisse fiyatlar\u0131n\u0131 \u00e7\u00f6kertir. DNLI i\u00e7in \u00f6zellikle yakla\u015fan Ocak karar\u0131, hisse senedinin k\u0131sa vadeli seyrini belirleyebilecek ikili bir olayd\u0131r.<\/p> <p><strong>6 Ayl\u0131k Fiyat Seyri: Dalgalarla Dolu Bir Yolculuk<\/strong><\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>\u00d6nemli Hareket<\/th><th>Kataliz\u00f6r<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>13,30 $ - 16,97 $<\/td><td>-%17,90<\/td><td>Genel piyasa volatilitesi<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>10,57 $ - 16,84 $<\/td><td>+%22,47<\/td><td>A\u015f\u0131r\u0131 volatilite, 52 haftan\u0131n en d\u00fc\u015f\u00fc\u011f\u00fc<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>12,86 $ - 16,97 $<\/td><td>-%20,48<\/td><td>Nisan art\u0131\u015f\u0131ndan sonra kar realizasyonu<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>12,94 $ - 15,69 $<\/td><td>+%5,66<\/td><td>Stabilizasyon a\u015famas\u0131<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>13,83 $ - 15,16 $<\/td><td>+%5,93<\/td><td>Devam eden toparlanma<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>~14,80 $ - 15,49 $<\/td><td>Stabilize oluyor<\/td><td>Mevcut seviyelere yakla\u015f\u0131yor<\/td><\/tr> <\/tbody> <\/table> <p>Hisse, bu d\u00f6nemde 10,57 $ (52 haftan\u0131n en d\u00fc\u015f\u00fc\u011f\u00fc) ile 16,97 $ aras\u0131nda a\u015f\u0131r\u0131 volatilite g\u00f6sterdi. Bu %60'tan fazla i\u015flem aral\u0131\u011f\u0131, DNLI'nin haber ak\u0131\u015f\u0131na ve piyasa duyarl\u0131l\u0131\u011f\u0131na ne kadar hassas oldu\u011funu ortaya koyuyor.<\/p> <p><strong>2025 2. \u00c7eyrek Kazan\u00e7 Etkisi Analizi<\/strong><\/p> <p>En son <a href=\"https:\/\/www.stocktitan.net\/news\/DNLI\/denali-therapeutics-reports-second-quarter-2025-financial-results-v83tbs195jyg.html\">11 A\u011fustos 2025<\/a> tarihli kazan\u00e7 raporu baz\u0131 ilgin\u00e7 dinamikleri ortaya koydu:<\/p> <ul> <li><strong>Net zarar<\/strong>: 124,1 milyon $ (2024 2. \u00e7eyrekte 99,0 milyon $'dan art\u0131\u015f)<\/li> <li><strong>Ar-Ge giderleri<\/strong>: 102,7 milyon $ (91,4 milyon $'dan art\u0131\u015f)<\/li> <li><strong>Hisse ba\u015f\u0131na kazan\u00e7 (EPS)<\/strong>: -0,72 $ (konsens\u00fcs tahmini -0,74 $'\u0131 0,02 $ a\u015farak)<\/li> <\/ul> <p>Zararlar\u0131n artmas\u0131na ra\u011fmen, piyasa nispeten sakin tepki verdi \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar klinik a\u015famadaki biyoteknoloji \u015firketlerinin nakit yakarak projelerini ilerlettiklerini anl\u0131yor. Kazan\u00e7 s\u00fcrprizi, ne kadar k\u00fc\u00e7\u00fck olursa olsun, operasyonel disiplinin g\u00f6stergesiydi.<\/p> <p><strong>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong><\/p> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firketin \u00fcr\u00fcn hatt\u0131 ilerlemesine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 24-28 $ aral\u0131\u011f\u0131 (mevcut fiyattan +%55-80)<br> - Kataliz\u00f6rler: Kas\u0131m kazan\u00e7lar\u0131, potansiyel ek d\u00fczenleyici ba\u015fvurular<br> - <strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/p> <p><strong>2026 Projeksiyonu<\/strong>: 30-35 $ aral\u0131\u011f\u0131 <br> - \u00d6nemli olay: 5 Ocak 2026 FDA karar\u0131 tividenofusp alfa i\u00e7in<br> - Onaylan\u0131rsa: 40-50 $ aral\u0131\u011f\u0131na s\u0131\u00e7rayabilir<br> - Reddedilirse: 8-12 $ aral\u0131\u011f\u0131na d\u00fc\u015febilir<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 45-60 $ aral\u0131\u011f\u0131<br> - Mevcut \u00fcr\u00fcn hatt\u0131n\u0131n ba\u015far\u0131l\u0131 ticarile\u015fmesi varsay\u0131m\u0131<br> - Birden fazla \u00fcr\u00fcn potansiyel olarak piyasada<\/p> <p><strong>2030 Vizyonu<\/strong>: 70-90+ $ aral\u0131\u011f\u0131<br> - Platform teknolojisi bir\u00e7ok hastal\u0131kta do\u011frulanm\u0131\u015f<br> - B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/p> <p><strong>\u26a0\ufe0f Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Temel Riskler<\/strong><\/p> <ul> <li><strong>Y\u00fcksek Volatilite Riski<\/strong>: DNLI g\u00fcnl\u00fck rutin haberlerde %5-10 aras\u0131nda dalgalan\u0131yor<\/li> <li><strong>D\u00fczenleyici Risk<\/strong>: FDA reddi an\u0131nda de\u011ferin %50'sinden fazlas\u0131n\u0131 silebilir<\/li> <li><strong>Klinik Deneme Riski<\/strong>: Devam eden \u00e7al\u0131\u015fmalardan olumsuz veriler y\u0131k\u0131c\u0131 olabilir<\/li> <li><strong>Nakit Yakma Riski<\/strong>: 977,4 milyon $ b\u00fcy\u00fck g\u00f6r\u00fcnse de biyoteknoloji Ar-Ge maliyetlidir<\/li> <li><strong>Hisse Seyrelme Riski<\/strong>: Ek sermaye art\u0131r\u0131m\u0131 i\u00e7in hisse ihrac\u0131 gerekebilir<\/li> <\/ul> <p><strong>\ud83d\udea6 2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p> <ul> <li><strong>FDA \u00d6ncelikli \u0130nceleme<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/07\/3110980\/0\/en\/Denali-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-Biologics-License-Application-BLA-for-Tividenofusp-Alfa-for-Hunter-Syndrome-MPS-II.html\">5 Ocak 2026 karar tarihi<\/a> net bir zaman \u00e7izelgesi olu\u015fturuyor<\/li> <li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 977,4 milyon $ 2+ y\u0131l \u00e7al\u0131\u015fma sermayesi sa\u011fl\u0131yor<\/li> <li><strong>Platform Do\u011frulamas\u0131<\/strong>: TransportVehicle\u2122 teknolojisi umut vaat ediyor<\/li> <li><strong>Piyasa Potansiyeli<\/strong>: Hunter sendromu tedavisi kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyaca hitap ediyor<\/li> <li><strong>Analist Deste\u011fi<\/strong>: <a href=\"https:\/\/stockanalysis.com\/stocks\/dnli\/forecast\/\">15 analist G\u00fc\u00e7l\u00fc Al\u0131m derecelendirmesi veriyor<\/a>, ortalama hedef fiyat 33,62 $<\/li> <\/ul> <p><strong>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Trader Bug\u00fcn Ne Yapmal\u0131?<\/strong><\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> - T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li> <li><strong>Stop-loss emirleri koyun<\/strong> - Felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 kendinizi koruyun<\/li> <li><strong>FDA takvimini takip edin<\/strong> - 5 Ocak 2026 tarihini k\u0131rm\u0131z\u0131 kal\u0131n harflerle i\u015faretleyin<\/li> <li><strong>Esprili ger\u00e7eklik kontrol\u00fc<\/strong>: \"DNLI ticareti k\u00f6r\u00fc k\u00f6r\u00fcne bir lunapark treni s\u00fcrmek gibidir\u2014y\u00fckseklik korkunuz oldu\u011funu hat\u0131rlayana kadar heyecan verici!\"<\/li> <\/ol> <p><strong>\u2705 Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/strong><\/p> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Genellikle 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"DNLI\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc belirleyin<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finizden fazlas\u0131n\u0131 riske atmay\u0131n<\/td><\/tr> <tr><td>7<\/td><td>Sat\u0131n al\u0131m\u0131 onaylay\u0131n<\/td><td>\u0130\u015flemi ger\u00e7ekle\u015ftirmeden \u00f6nce t\u00fcm detaylar\u0131 iki kez kontrol edin<\/td><\/tr> <tr><td>8<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>\u00d6nemli fiyat seviyelerini takip edin<\/td><\/tr> <tr><td>9<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>K\u00e2r alaca\u011f\u0131n\u0131z veya zarar\u0131 kesece\u011finiz zaman\u0131 bilin<\/td><\/tr> <tr><td>10<\/td><td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><td>Biyoteknoloji aktif takip gerektirir<\/td><\/tr> <\/tbody> <\/table> <p><strong>\ud83d\udca1 Pocket Option'un Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/strong><\/p> <p>DNLI gibi biyoteknoloji hisseleriyle denemek isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> - \u00d6nemli risk olmadan \u00f6\u011frenmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Hesap olu\u015fturduktan dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> - DNLI hissesi i\u00e7in 15,49 $ tam hisseye gerek kalmadan par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - Volatil hisselerde yeni ba\u015flayanlar i\u00e7in sezgisel aray\u00fcz<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Pocket Option blogu \u00fczerinden biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda bilgi edinin<\/li> <\/ul> <p><strong>\ud83c\udf0d 2025'te Denali Therapeutics: N\u00f6robilimde \u00d6nc\u00fc<\/strong><\/p> <p>Denali Therapeutics, t\u0131bb\u0131n en zorlu n\u00f6rolojik hastal\u0131klar\u0131n\u0131n tedavisinde \u00f6n saflarda yer al\u0131yor. \u015eirketin TransportVehicle\u2122 platformu, kan-beyin bariyerini a\u015farak tedavileri ula\u015ft\u0131rmada \u00e7\u0131\u011f\u0131r a\u00e7an bir yakla\u015f\u0131m\u0131 temsil ediyor\u2014bu, ara\u015ft\u0131rmac\u0131lar\u0131n onlarca y\u0131ld\u0131r \u00e7\u00f6zmeye \u00e7al\u0131\u015ft\u0131\u011f\u0131 bir zorluk.<\/p> <p>\u015eu anda Denali, lizozomal depo hastal\u0131klar\u0131 ve n\u00f6rodejeneratif bozukluklar\u0131 hedefleyen birden fazla klinik program\u0131 ilerletiyor. Lider aday\u0131 tividenofusp alfa, Hunter sendromunun hem fiziksel hem de n\u00f6rolojik semptomlar\u0131n\u0131 etkili \u015fekilde tedavi eden ilk terapi olabilir.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Denali yak\u0131n zamanda Salt Lake City'de son teknoloji bir klinik biyoproduksiyon tesisi a\u00e7t\u0131\u2014ama i\u015fin g\u00fczel yan\u0131: bu tesis, protein \u00fcretim s\u00fcre\u00e7lerini optimize etmek i\u00e7in yapay zeka destekli robotik kullan\u0131yor ve geleneksel y\u00f6ntemlere k\u0131yasla \u00fcretim s\u00fcresini %40 azalt\u0131yor. Yani yapay zekay\u0131 biyolojik zek\u00e2 yaratmak i\u00e7in kullan\u0131yorlar!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<p>\ud83d\udcc8 <strong>G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/strong><\/p>\n<p>26 A\u011fustos 2025 itibar\u0131yla Denali Therapeutics Inc. (DNLI) hissesi <strong>15,49 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014DNLI&#8217;nin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar hisseyi \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirmi\u015f, bazen saatler i\u00e7inde \u00e7ift haneli y\u00fczdelerle de\u011fi\u015fim g\u00f6stermi\u015ftir.<\/p>\n<p><strong>FDA Kararlar\u0131n\u0131n DNLI Hissesini Nas\u0131l Etkiledi\u011fi<\/strong><\/p>\n<p>Biyoteknoloji hisseleri d\u00fczenleyici haberlerle hayat bulur ya da biter, DNLI de istisna de\u011fil. \u015eirket yak\u0131n zamanda lider ila\u00e7 aday\u0131 tividenofusp alfa i\u00e7in <a href=\"https:\/\/www.stocktitan.net\/news\/DNLI\/denali-therapeutics-announces-fda-acceptance-and-priority-review-of-1lxq6gfuzvfz.html\">FDA taraf\u0131ndan \u00d6ncelikli \u0130nceleme kabul\u00fc<\/a> ald\u0131 ve PDUFA hedef tarihi 5 Ocak 2026 olarak belirlendi. Bu b\u00fcy\u00fck bir haber\u2014\u00d6ncelikli \u0130nceleme, FDA&#8217;n\u0131n bu tedaviyi mevcut tedavilere k\u0131yasla \u00f6nemli bir ilerleme olarak g\u00f6rd\u00fc\u011f\u00fc anlam\u0131na gelir.<\/p>\n<p>Tarihsel desenlere bak\u0131ld\u0131\u011f\u0131nda, olumlu FDA haberleri genellikle biyoteknoloji hisselerini tek bir g\u00fcnde %20-50 oran\u0131nda y\u00fckseltir. Tersi de do\u011frudur\u2014d\u00fczenleyici aksakl\u0131klar hisse fiyatlar\u0131n\u0131 \u00e7\u00f6kertir. DNLI i\u00e7in \u00f6zellikle yakla\u015fan Ocak karar\u0131, hisse senedinin k\u0131sa vadeli seyrini belirleyebilecek ikili bir olayd\u0131r.<\/p>\n<p><strong>6 Ayl\u0131k Fiyat Seyri: Dalgalarla Dolu Bir Yolculuk<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>\u00d6nemli Hareket<\/th>\n<th>Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>13,30 $ &#8211; 16,97 $<\/td>\n<td>-%17,90<\/td>\n<td>Genel piyasa volatilitesi<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>10,57 $ &#8211; 16,84 $<\/td>\n<td>+%22,47<\/td>\n<td>A\u015f\u0131r\u0131 volatilite, 52 haftan\u0131n en d\u00fc\u015f\u00fc\u011f\u00fc<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>12,86 $ &#8211; 16,97 $<\/td>\n<td>-%20,48<\/td>\n<td>Nisan art\u0131\u015f\u0131ndan sonra kar realizasyonu<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>12,94 $ &#8211; 15,69 $<\/td>\n<td>+%5,66<\/td>\n<td>Stabilizasyon a\u015famas\u0131<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>13,83 $ &#8211; 15,16 $<\/td>\n<td>+%5,93<\/td>\n<td>Devam eden toparlanma<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>~14,80 $ &#8211; 15,49 $<\/td>\n<td>Stabilize oluyor<\/td>\n<td>Mevcut seviyelere yakla\u015f\u0131yor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse, bu d\u00f6nemde 10,57 $ (52 haftan\u0131n en d\u00fc\u015f\u00fc\u011f\u00fc) ile 16,97 $ aras\u0131nda a\u015f\u0131r\u0131 volatilite g\u00f6sterdi. Bu %60&#8217;tan fazla i\u015flem aral\u0131\u011f\u0131, DNLI&#8217;nin haber ak\u0131\u015f\u0131na ve piyasa duyarl\u0131l\u0131\u011f\u0131na ne kadar hassas oldu\u011funu ortaya koyuyor.<\/p>\n<p><strong>2025 2. \u00c7eyrek Kazan\u00e7 Etkisi Analizi<\/strong><\/p>\n<p>En son <a href=\"https:\/\/www.stocktitan.net\/news\/DNLI\/denali-therapeutics-reports-second-quarter-2025-financial-results-v83tbs195jyg.html\">11 A\u011fustos 2025<\/a> tarihli kazan\u00e7 raporu baz\u0131 ilgin\u00e7 dinamikleri ortaya koydu:<\/p>\n<ul>\n<li><strong>Net zarar<\/strong>: 124,1 milyon $ (2024 2. \u00e7eyrekte 99,0 milyon $&#8217;dan art\u0131\u015f)<\/li>\n<li><strong>Ar-Ge giderleri<\/strong>: 102,7 milyon $ (91,4 milyon $&#8217;dan art\u0131\u015f)<\/li>\n<li><strong>Hisse ba\u015f\u0131na kazan\u00e7 (EPS)<\/strong>: -0,72 $ (konsens\u00fcs tahmini -0,74 $&#8217;\u0131 0,02 $ a\u015farak)<\/li>\n<\/ul>\n<p>Zararlar\u0131n artmas\u0131na ra\u011fmen, piyasa nispeten sakin tepki verdi \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar klinik a\u015famadaki biyoteknoloji \u015firketlerinin nakit yakarak projelerini ilerlettiklerini anl\u0131yor. Kazan\u00e7 s\u00fcrprizi, ne kadar k\u00fc\u00e7\u00fck olursa olsun, operasyonel disiplinin g\u00f6stergesiydi.<\/p>\n<p><strong>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong><\/p>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firketin \u00fcr\u00fcn hatt\u0131 ilerlemesine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 24-28 $ aral\u0131\u011f\u0131 (mevcut fiyattan +%55-80)<br \/> &#8211; Kataliz\u00f6rler: Kas\u0131m kazan\u00e7lar\u0131, potansiyel ek d\u00fczenleyici ba\u015fvurular<br \/> &#8211; <strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 30-35 $ aral\u0131\u011f\u0131 <br \/> &#8211; \u00d6nemli olay: 5 Ocak 2026 FDA karar\u0131 tividenofusp alfa i\u00e7in<br \/> &#8211; Onaylan\u0131rsa: 40-50 $ aral\u0131\u011f\u0131na s\u0131\u00e7rayabilir<br \/> &#8211; Reddedilirse: 8-12 $ aral\u0131\u011f\u0131na d\u00fc\u015febilir<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 45-60 $ aral\u0131\u011f\u0131<br \/> &#8211; Mevcut \u00fcr\u00fcn hatt\u0131n\u0131n ba\u015far\u0131l\u0131 ticarile\u015fmesi varsay\u0131m\u0131<br \/> &#8211; Birden fazla \u00fcr\u00fcn potansiyel olarak piyasada<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 70-90+ $ aral\u0131\u011f\u0131<br \/> &#8211; Platform teknolojisi bir\u00e7ok hastal\u0131kta do\u011frulanm\u0131\u015f<br \/> &#8211; B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/p>\n<p><strong>\u26a0\ufe0f Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Temel Riskler<\/strong><\/p>\n<ul>\n<li><strong>Y\u00fcksek Volatilite Riski<\/strong>: DNLI g\u00fcnl\u00fck rutin haberlerde %5-10 aras\u0131nda dalgalan\u0131yor<\/li>\n<li><strong>D\u00fczenleyici Risk<\/strong>: FDA reddi an\u0131nda de\u011ferin %50&#8217;sinden fazlas\u0131n\u0131 silebilir<\/li>\n<li><strong>Klinik Deneme Riski<\/strong>: Devam eden \u00e7al\u0131\u015fmalardan olumsuz veriler y\u0131k\u0131c\u0131 olabilir<\/li>\n<li><strong>Nakit Yakma Riski<\/strong>: 977,4 milyon $ b\u00fcy\u00fck g\u00f6r\u00fcnse de biyoteknoloji Ar-Ge maliyetlidir<\/li>\n<li><strong>Hisse Seyrelme Riski<\/strong>: Ek sermaye art\u0131r\u0131m\u0131 i\u00e7in hisse ihrac\u0131 gerekebilir<\/li>\n<\/ul>\n<p><strong>\ud83d\udea6 2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p>\n<ul>\n<li><strong>FDA \u00d6ncelikli \u0130nceleme<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/07\/3110980\/0\/en\/Denali-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-Biologics-License-Application-BLA-for-Tividenofusp-Alfa-for-Hunter-Syndrome-MPS-II.html\">5 Ocak 2026 karar tarihi<\/a> net bir zaman \u00e7izelgesi olu\u015fturuyor<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 977,4 milyon $ 2+ y\u0131l \u00e7al\u0131\u015fma sermayesi sa\u011fl\u0131yor<\/li>\n<li><strong>Platform Do\u011frulamas\u0131<\/strong>: TransportVehicle\u2122 teknolojisi umut vaat ediyor<\/li>\n<li><strong>Piyasa Potansiyeli<\/strong>: Hunter sendromu tedavisi kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyaca hitap ediyor<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: <a href=\"https:\/\/stockanalysis.com\/stocks\/dnli\/forecast\/\">15 analist G\u00fc\u00e7l\u00fc Al\u0131m derecelendirmesi veriyor<\/a>, ortalama hedef fiyat 33,62 $<\/li>\n<\/ul>\n<p><strong>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Trader Bug\u00fcn Ne Yapmal\u0131?<\/strong><\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> &#8211; T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li>\n<li><strong>Stop-loss emirleri koyun<\/strong> &#8211; Felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 kendinizi koruyun<\/li>\n<li><strong>FDA takvimini takip edin<\/strong> &#8211; 5 Ocak 2026 tarihini k\u0131rm\u0131z\u0131 kal\u0131n harflerle i\u015faretleyin<\/li>\n<li><strong>Esprili ger\u00e7eklik kontrol\u00fc<\/strong>: &#8220;DNLI ticareti k\u00f6r\u00fc k\u00f6r\u00fcne bir lunapark treni s\u00fcrmek gibidir\u2014y\u00fckseklik korkunuz oldu\u011funu hat\u0131rlayana kadar heyecan verici!&#8221;<\/li>\n<\/ol>\n<p><strong>\u2705 Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;DNLI&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc belirleyin<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finizden fazlas\u0131n\u0131 riske atmay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Sat\u0131n al\u0131m\u0131 onaylay\u0131n<\/td>\n<td>\u0130\u015flemi ger\u00e7ekle\u015ftirmeden \u00f6nce t\u00fcm detaylar\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>\u00d6nemli fiyat seviyelerini takip edin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>K\u00e2r alaca\u011f\u0131n\u0131z veya zarar\u0131 kesece\u011finiz zaman\u0131 bilin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<td>Biyoteknoloji aktif takip gerektirir<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\ud83d\udca1 Pocket Option&#8217;un Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/strong><\/p>\n<p>DNLI gibi biyoteknoloji hisseleriyle denemek isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> &#8211; \u00d6nemli risk olmadan \u00f6\u011frenmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Hesap olu\u015fturduktan dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> &#8211; DNLI hissesi i\u00e7in 15,49 $ tam hisseye gerek kalmadan par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; Volatil hisselerde yeni ba\u015flayanlar i\u00e7in sezgisel aray\u00fcz<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Pocket Option blogu \u00fczerinden biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda bilgi edinin<\/li>\n<\/ul>\n<p><strong>\ud83c\udf0d 2025&#8217;te Denali Therapeutics: N\u00f6robilimde \u00d6nc\u00fc<\/strong><\/p>\n<p>Denali Therapeutics, t\u0131bb\u0131n en zorlu n\u00f6rolojik hastal\u0131klar\u0131n\u0131n tedavisinde \u00f6n saflarda yer al\u0131yor. \u015eirketin TransportVehicle\u2122 platformu, kan-beyin bariyerini a\u015farak tedavileri ula\u015ft\u0131rmada \u00e7\u0131\u011f\u0131r a\u00e7an bir yakla\u015f\u0131m\u0131 temsil ediyor\u2014bu, ara\u015ft\u0131rmac\u0131lar\u0131n onlarca y\u0131ld\u0131r \u00e7\u00f6zmeye \u00e7al\u0131\u015ft\u0131\u011f\u0131 bir zorluk.<\/p>\n<p>\u015eu anda Denali, lizozomal depo hastal\u0131klar\u0131 ve n\u00f6rodejeneratif bozukluklar\u0131 hedefleyen birden fazla klinik program\u0131 ilerletiyor. Lider aday\u0131 tividenofusp alfa, Hunter sendromunun hem fiziksel hem de n\u00f6rolojik semptomlar\u0131n\u0131 etkili \u015fekilde tedavi eden ilk terapi olabilir.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Denali yak\u0131n zamanda Salt Lake City&#8217;de son teknoloji bir klinik biyoproduksiyon tesisi a\u00e7t\u0131\u2014ama i\u015fin g\u00fczel yan\u0131: bu tesis, protein \u00fcretim s\u00fcre\u00e7lerini optimize etmek i\u00e7in yapay zeka destekli robotik kullan\u0131yor ve geleneksel y\u00f6ntemlere k\u0131yasla \u00fcretim s\u00fcresini %40 azalt\u0131yor. Yani yapay zekay\u0131 biyolojik zek\u00e2 yaratmak i\u00e7in kullan\u0131yorlar!<\/p>\n"},"faq":[{"question":"Denali Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, DNLI sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve d\u00fczenli olarak pozisyonunuzu takip edin."},{"question":"DNLI hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"FDA kararlar\u0131, klinik deneme sonu\u00e7lar\u0131, piyasa volatilitesi ve \u015firketin finansal performans\u0131 DNLI hisselerinin fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler."},{"question":"FDA \u00d6ncelikli \u0130nceleme nedir ve DNLI i\u00e7in neden \u00f6nemlidir?","answer":"FDA \u00d6ncelikli \u0130nceleme, bir tedavinin mevcut tedavilere g\u00f6re \u00f6nemli bir ilerleme oldu\u011funu g\u00f6sterir ve onay s\u00fcrec\u00fcn\u00fc h\u0131zland\u0131r\u0131r. DNLI'nin tividenofusp alfa ilac\u0131 i\u00e7in bu stat\u00fc, hisse i\u00e7in olumlu bir kataliz\u00f6rd\u00fcr."},{"question":"Yeni ba\u015flayan biri DNLI hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, stop-loss emirleri kullan\u0131n ve FDA karar tarihlerini yak\u0131ndan takip edin."},{"question":"Denali Therapeutics'in 2025 sonras\u0131 i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 24-28 $ aral\u0131\u011f\u0131nda olabilir, 2026 FDA karar\u0131 sonras\u0131 ise 30-50 $ aras\u0131nda dalgalanabilir. Uzun vadede 2030'a kadar 70-90 $ ve \u00fczeri hedeflenmektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Denali Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, DNLI sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve d\u00fczenli olarak pozisyonunuzu takip edin."},{"question":"DNLI hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"FDA kararlar\u0131, klinik deneme sonu\u00e7lar\u0131, piyasa volatilitesi ve \u015firketin finansal performans\u0131 DNLI hisselerinin fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler."},{"question":"FDA \u00d6ncelikli \u0130nceleme nedir ve DNLI i\u00e7in neden \u00f6nemlidir?","answer":"FDA \u00d6ncelikli \u0130nceleme, bir tedavinin mevcut tedavilere g\u00f6re \u00f6nemli bir ilerleme oldu\u011funu g\u00f6sterir ve onay s\u00fcrec\u00fcn\u00fc h\u0131zland\u0131r\u0131r. DNLI'nin tividenofusp alfa ilac\u0131 i\u00e7in bu stat\u00fc, hisse i\u00e7in olumlu bir kataliz\u00f6rd\u00fcr."},{"question":"Yeni ba\u015flayan biri DNLI hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, stop-loss emirleri kullan\u0131n ve FDA karar tarihlerini yak\u0131ndan takip edin."},{"question":"Denali Therapeutics'in 2025 sonras\u0131 i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 24-28 $ aral\u0131\u011f\u0131nda olabilir, 2026 FDA karar\u0131 sonras\u0131 ise 30-50 $ aras\u0131nda dalgalanabilir. Uzun vadede 2030'a kadar 70-90 $ ve \u00fczeri hedeflenmektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T08:37:09+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T08:37:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\",\"name\":\"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-26T08:37:09+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T08:37:09+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T08:37:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/","name":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r - Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-26T08:37:09+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-denali-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Denali Therapeutics Inc. (DNLI) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Denali Therapeutics Inc. (DNLI) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":352912,"slug":"how-to-buy-denali-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Denali Therapeutics Inc. (DNLI) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Denali Therapeutics Inc. (DNLI)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-denali-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":352906,"slug":"how-to-buy-denali-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Denali Therapeutics Inc. (DNLI) - Investimento em a\u00e7\u00f5es da Denali Therapeutics Inc. (DNLI)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-denali-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=352910"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352910\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=352910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=352910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=352910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}